Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 3
2017 1
2019 3
2020 2
2021 5
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: de novi la. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, Cappelli LV, Ilari C, Cafforio L, Guarini A, Foà R. Del Giudice I, et al. Among authors: de novi la. Front Oncol. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689. eCollection 2019. Front Oncol. 2019. PMID: 31555576 Free PMC article. Review.
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Soscia R, Della Starza I, De Novi LA, Ilari C, Ansuinelli M, Cavalli M, Bellomarino V, Cafforio L, Di Trani M, Cazzaniga G, Fazio G, Santoro A, Salemi D, Spinelli O, Tosi M, Terragna C, Robustelli V, Bellissimo T, Colafigli G, Breccia M, Chiaretti S, Di Rocco A, Martelli M, Guarini A, Del Giudice I, Foà R. Soscia R, et al. Among authors: de novi la. Hematol Oncol. 2023 Feb;41(1):50-60. doi: 10.1002/hon.3087. Epub 2022 Oct 19. Hematol Oncol. 2023. PMID: 36251440
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.
Chiaretti S, Taherinasab A, Della Starza I, Canichella M, Ansuinelli M, De Propris MS, Messina M, Spinelli O, Santoro A, De Novi LA, Cardinali D, Schipani M, Arena V, Bassan R, Guarini A, Foà R. Chiaretti S, et al. Among authors: de novi la. Leuk Lymphoma. 2023 Feb;64(2):483-486. doi: 10.1080/10428194.2022.2148217. Epub 2022 Dec 19. Leuk Lymphoma. 2023. PMID: 36533589 No abstract available.
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A. Della Starza I, et al. Among authors: de novi la. Leuk Lymphoma. 2019 Nov;60(11):2838-2840. doi: 10.1080/10428194.2019.1607325. Epub 2019 May 3. Leuk Lymphoma. 2019. PMID: 31050551 No abstract available.
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia.
Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, Campeggio M, De Novi LA, Soscia R, Oggioni C, Mussolin L, Biondi A, Guarini A, Valsecchi MG, Conter V, Biffi A, Basso G, Foà R, Cazzaniga G. Della Starza I, et al. Among authors: de novi la. Hemasphere. 2021 Feb 24;5(3):e543. doi: 10.1097/HS9.0000000000000543. eCollection 2021 Mar. Hemasphere. 2021. PMID: 33655199 Free PMC article.
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network.
Mantoan B, Genuardi E, Ferrante M, Della Starza I, Ciabatti E, Grassi S, De Novi LA, Cavalli M, Mannu C, Gazzola A, Bomben R, Degan M, Alessandria B, Pott C, Delfau-Larue MH, García-Sanz R, Agostinelli C, Gattei V, Galimberti S, Del Giudice I, Gaidano G, Ladetto M, Ferrero S, Drandi D. Mantoan B, et al. Among authors: de novi la. Hemasphere. 2021 Sep 6;5(10):e639. doi: 10.1097/HS9.0000000000000639. eCollection 2021 Oct. Hemasphere. 2021. PMID: 34514343 Free PMC article. No abstract available.
18 results